(Q37272559)

19 August 2017

1 reference

title

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation (English)

1 reference

myeloproliferative disorders

19 August 2017

0 references

0 references

1 reference

R Landolfi

1

1 reference

19 August 2017

L Di Gennaro

series ordinal

2

1 reference

19 August 2017

A Falanga

series ordinal

3

1 reference

19 August 2017

18 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

22

1 reference

19 August 2017

11

1 reference

19 August 2017

2020-2028

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.253

19 August 2017

0 references

cites work

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

Platelet Hyperaggregability and Thrombosis in Patients with Thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Erythromelalgia: review of clinical characteristics and pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Transient neurologic and ocular manifestations in primary thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Acute coronary disease in essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Cardiac involvement in patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Hyperviscosity in polycythemia vera and other red cell abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Platelet and red cell involvement in mural thrombogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Aggregation and disaggregation kinetics of human blood platelets: Part III. The disaggregation under shear stress of platelet aggregates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Red blood cells: their dual role in thrombus formation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

The red blood cell in vascular occlusion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Leukocyte adhesion and thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

P-selectin induces the expression of tissue factor on monocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Increased neutrophil-platelet adhesion in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Prevention of thrombosis in polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Low-dose aspirin for the prevention of atherothrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

P-selectin and leukocyte microparticles are associated with venous thrombogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.253

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.253

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference